Abstract
Coronavirus disease 2019 is delaying the diagnosis and management of chest pain, acute coronary syndromes, myocarditis and heart failure.
Highlights
“Given the importance of timely management of myocardial infarction in COVID-19 patients, ” clinicians must be able to distinguish true acute coronary syndrome (ACS) from ACS mimics among these patients
COVID-19 has imposed an unfortunate conundrum: the disease is significantly associated with death in patients with pre-existing cardiovascular disease, [1,2] and yet hospital admissions and certain cardiac procedures have significantly declined compared with prior years [3,4,5]
The way in which certain centers approach the diagnosis of ACS or myocardial infarction in COVID-19 patients may have contributed to the decline in the apparent incidence of ischemic heart disease
Summary
“Given the importance of timely management of myocardial infarction in COVID-19 patients, ” clinicians must be able to distinguish true ACS from ACS mimics among these patients. This creates a potentially multiplicative problem if COVID19 and its etiologic virus, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), directly or indirectly cause increased cardiac damage while patients with cardiac disease are simultaneously undertreated for pre-existing or de novo illness.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
